# Wegovy pill is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management.

*biotech · news · 2026-06-07 · MarketScreener*

## Key points

- The UAE is the first country outside the US to launch the Wegovy pill.
- Wegovy pill's weight loss results are similar to injectable Wegovy, achieving about 17% mean weight loss.
- One in three participants in the OASIS 4 trial lost 20% or more of their body weight.
- Wegovy pill is the only weight-loss pill approved by both the FDA and EDE to reduce MACE risk.

Novo Nordisk announced the launch of Wegovy pill (semaglutide tablets) in the United Arab Emirates (UAE), the first country outside the United States to make the Wegovy pill available to people living with obesity. The Wegovy pill is the first oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management. The approval is based on the OASIS 4 trial programme. In the OASIS 4 trial, oral semaglutide 25 mg taken once daily demonstrated ~17% mean weight loss when treatment was adhered to in adult participants with obesity or overweight with one or more comorbidities. The weight loss achieved with the Wegovy pill is similar to that of injectable Wegovy 2.4 mg. Furthermore, 1 in 3 people experienced 20% or greater weight loss in the OASIS 4 trial. The established safety and tolerability profile of semaglutide was reaffirmed with Wegovy pill in the OASIS-4 trial, which was comparable to previous trials with semaglutide for weight management. Wegovy pill is also the only weight-loss pill approved by both the FDA and the Emirates Drug Establishment (EDE) to reduce the risk of major adverse cardiovascular events (MACE), including heart attack and stroke, in adults with established cardiovascular disease and obesity or overweight. Novo Nordisk has previously announced that we will launch Wegovy pill in select markets in the second half of 2026.

**Companies:** Novo Nordisk
**Countries:** United Arab Emirates, United States

[Read the full story on MarketScreener](https://www.marketscreener.com/news/novo-nordisk-launches-wegovy-pill-in-the-united-arab-emirates-ce7f5dd2dc88f126)

---

Canonical: https://newsio.io/n/8b6a9b29-464c-43da-81b2-e758f304c884/wegovy-pill-is-the-first-oral-glucagon-like-peptide-1-glp-1-receptor-agonist-the
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works